Sientra (NASDAQ:SIEN) released its quarterly earnings results on Tuesday. The medical instruments supplier reported ($0.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.05), Briefing.com reports. The company had revenue of $16.90 million during the quarter, compared to analysts’ expectations of $16.66 million. Sientra had a negative return on equity of 162.07% and a negative net margin of 126.03%. The firm’s revenue was up 72.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.74) EPS.
Shares of SIEN traded up $0.04 during trading on Thursday, reaching $20.85. The company’s stock had a trading volume of 34,063 shares, compared to its average volume of 289,929. Sientra has a twelve month low of $8.79 and a twelve month high of $26.79. The firm has a market cap of $606.36 million, a price-to-earnings ratio of -7.39 and a beta of -0.37. The company has a quick ratio of 2.63, a current ratio of 3.06 and a debt-to-equity ratio of 0.27.
In other Sientra news, CEO Jeffrey M. Nugent sold 1,852 shares of the company’s stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $24.90, for a total value of $46,114.80. Following the transaction, the chief executive officer now directly owns 297,999 shares of the company’s stock, valued at approximately $7,420,175.10. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 31.00% of the company’s stock.
A number of research firms have weighed in on SIEN. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a report on Wednesday. Canaccord Genuity upped their price target on Sientra from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. BidaskClub cut Sientra from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Dougherty & Co began coverage on Sientra in a report on Thursday, August 30th. They issued a “buy” rating and a $31.00 price target for the company. Finally, Stephens restated a “buy” rating and issued a $30.00 price target on shares of Sientra in a report on Thursday, August 9th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Sientra has a consensus rating of “Buy” and an average target price of $22.50.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Further Reading: How Do I Invest in Dividend Stocks
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.